JP7334041B2 - トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用 - Google Patents

トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用 Download PDF

Info

Publication number
JP7334041B2
JP7334041B2 JP2018511057A JP2018511057A JP7334041B2 JP 7334041 B2 JP7334041 B2 JP 7334041B2 JP 2018511057 A JP2018511057 A JP 2018511057A JP 2018511057 A JP2018511057 A JP 2018511057A JP 7334041 B2 JP7334041 B2 JP 7334041B2
Authority
JP
Japan
Prior art keywords
nhr
optionally substituted
nhc
aryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018511057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525430A (ja
JP2018525430A5 (enExample
Inventor
デスモンド パルマー ブライアン
チン ライ－ミン
Original Assignee
オークランド ユニサービシーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オークランド ユニサービシーズ リミティド filed Critical オークランド ユニサービシーズ リミティド
Publication of JP2018525430A publication Critical patent/JP2018525430A/ja
Publication of JP2018525430A5 publication Critical patent/JP2018525430A5/ja
Priority to JP2021182007A priority Critical patent/JP2022033753A/ja
Application granted granted Critical
Publication of JP7334041B2 publication Critical patent/JP7334041B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2018511057A 2015-08-27 2016-08-25 トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用 Active JP7334041B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021182007A JP2022033753A (ja) 2015-08-27 2021-11-08 トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ71151415 2015-08-27
NZ711514 2015-08-27
PCT/NZ2016/050135 WO2017034420A1 (en) 2015-08-27 2016-08-25 Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021182007A Division JP2022033753A (ja) 2015-08-27 2021-11-08 トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用

Publications (3)

Publication Number Publication Date
JP2018525430A JP2018525430A (ja) 2018-09-06
JP2018525430A5 JP2018525430A5 (enExample) 2019-10-10
JP7334041B2 true JP7334041B2 (ja) 2023-08-28

Family

ID=58100623

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018511057A Active JP7334041B2 (ja) 2015-08-27 2016-08-25 トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用
JP2021182007A Pending JP2022033753A (ja) 2015-08-27 2021-11-08 トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021182007A Pending JP2022033753A (ja) 2015-08-27 2021-11-08 トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用

Country Status (9)

Country Link
US (2) US11414428B2 (enExample)
EP (1) EP3350188B1 (enExample)
JP (2) JP7334041B2 (enExample)
KR (1) KR20180048798A (enExample)
CN (1) CN108349997B (enExample)
AU (2) AU2016312848A1 (enExample)
CA (1) CA2996681C (enExample)
WO (1) WO2017034420A1 (enExample)
ZA (1) ZA201800787B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2996681C (en) * 2015-08-27 2024-04-09 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
US11103511B2 (en) 2017-06-05 2021-08-31 Fudan University Substituted indolo[2,1-b]quinazolines as inhibitors of tryptophan dioxygenase and indoleamine 2,3-dioxygenase 1
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
TWI873098B (zh) 2018-07-03 2025-02-21 瑞士商諾華製藥公司 用於治療與sting活性相關之病症的化合物及組合物
JP2024502474A (ja) 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物
BR112023017582A2 (pt) 2021-03-05 2023-12-05 Univ Basel Composições para o tratamento de doenças ou condições associadas ao ebv
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
EP4486342A2 (en) 2022-03-04 2025-01-08 Antido Therapeutics International Sàrl Dual inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536884A (ja) 2005-04-20 2008-09-11 サノフィ−アベンティス リパーゼ及びホスホリパーゼの阻害剤の形態のアゾール誘導体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079193A2 (en) 2000-04-14 2001-10-25 Corvas International, Inc. Substituted hydrazinyl heteroaromatic inhibitors of thrombin
WO2005089753A2 (en) * 2004-03-16 2005-09-29 Janssen Pharmaceutica N.V. Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
DE102005038947A1 (de) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
DE102005026194A1 (de) * 2005-06-06 2006-12-07 Grünenthal GmbH Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
JP2012520246A (ja) 2009-03-10 2012-09-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３モジュレータとしての置換された３−アミノイソオキサゾロピリジン
MX2012009377A (es) 2010-02-11 2012-09-12 Univ Vanderbilt Benzotiazoles y azabenzotiazoles como potenciadores alostericos mglur4, composiciones y metodos para tratar la disfuncion neurologica.
BR112013001474B8 (pt) 2010-07-22 2018-05-22 Basf Se uso de compostos de isoxazolo[5,4-b]piridina, compostos de isoxazolo[5,4-b]piridina, composição, método para preparar uma composição e método para controlar vegetação indesejada
BR112014017209A8 (pt) 2012-01-12 2017-07-04 Basf Se compostos, composição, método para a preparação de uma composição e método para o controle da vegetação indesejável
PL220630B1 (pl) 2012-12-28 2015-11-30 Inst Immunologii I Terapii Doświadczalnej Pan Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny
JP6603649B2 (ja) 2013-03-14 2019-11-06 キュラデブ ファーマ プライベート リミテッド キヌレニン経路の阻害剤
EP3082802B1 (en) 2013-12-03 2020-02-26 Iomet Pharma Ltd. Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use
WO2016024233A1 (en) * 2014-08-13 2016-02-18 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
CA2996681C (en) * 2015-08-27 2024-04-09 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
RU2619120C1 (ru) * 2016-06-06 2017-05-12 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" 5-Хлор-3-(3-хлорфенилкарбоксамидо)-4,6-диметилизоксазоло[5,4-b]пиридин в качестве антидота 2,4-Д на подсолнечнике

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536884A (ja) 2005-04-20 2008-09-11 サノフィ−アベンティス リパーゼ及びホスホリパーゼの阻害剤の形態のアゾール誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ａｃｔａ Ｐｏｌｏｎｉａｅ Ｐｈａｒｍａｃｅｕｔｉｃａ－Ｄｒｕｇ Ｒｅｓｅａｒｃｈ，２００３， Ｖｏｌ．６０， Ｎｏ．４，ｐｐ．２９３－３０１
Ａｃｔａ Ｐｏｌｏｎｉａｅ Ｐｈａｒｍａｃｅｕｔｉｃａ－Ｄｒｕｇ Ｒｅｓｅａｒｃｈ，２０１５．０８．０３， Ｖｏｌ．７２， Ｎｏ．４，ｐｐ．７２７－７３５

Also Published As

Publication number Publication date
CN108349997A (zh) 2018-07-31
AU2021212003A1 (en) 2021-08-26
JP2018525430A (ja) 2018-09-06
WO2017034420A1 (en) 2017-03-02
KR20180048798A (ko) 2018-05-10
US20220411438A1 (en) 2022-12-29
CA2996681A1 (en) 2017-03-02
ZA201800787B (en) 2025-08-27
AU2016312848A1 (en) 2018-03-29
CN108349997B (zh) 2025-06-10
US20180244692A1 (en) 2018-08-30
EP3350188A1 (en) 2018-07-25
HK1258665A1 (en) 2019-11-15
AU2021212003B2 (en) 2023-09-14
EP3350188A4 (en) 2019-04-03
JP2022033753A (ja) 2022-03-02
US11414428B2 (en) 2022-08-16
CA2996681C (en) 2024-04-09
EP3350188B1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
AU2021212003B2 (en) INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY
US12508268B2 (en) Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy
TWI851542B (zh) Ｓｈｐ２之八氫環戊烷并[c]吡咯別構抑制劑
US10774065B2 (en) 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
RU2744988C2 (ru) Соединения и композиции для подавления активности shp2
JP6830948B2 (ja) Ｍｉｄｈ１阻害剤としての縮合イミダゾール
CN111065393A (zh) 用于治疗皮肤疾病的吡咯并吡啶-苯胺类化合物
US20190144437A1 (en) Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
WO2022015670A1 (en) Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors
JP2025509886A (ja) サイクリン依存性キナーゼ２阻害剤としてのスルホンアミド誘導体
HK1258665B (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
HK1238549B (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
HK1238549A1 (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190823

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211108

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211108

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220105

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220111

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220218

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220222

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230124

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230328

C302 Record of communication

Free format text: JAPANESE INTERMEDIATE CODE: C302

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230816

R150 Certificate of patent or registration of utility model

Ref document number: 7334041

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150